UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
Key Details
- 1AI stratified patients by tumor cell density on diagnostic biopsy slides in a post-hoc ARISTOTLE phase III trial analysis (n=414).
- 2Adding irinotecan reduced recurrence by 43% and death by 50% over 5 years in high-tumor-cell-density cases; no benefit in low-density cases.
- 3AI tool ('Octopath') enables rapid, large-scale analysis of digital pathology slides.
- 4Manual quantification was previously impractical for large studies; automation enables scalable, individualized treatment decisions.
- 5Further verification and studies are needed before clinical deployment.
Why It Matters
AI-driven analysis of biopsy pathology can enable more precise, personalized cancer therapy selection, sparing patients from unnecessary side effects and improving survival. This study underscores AI's value in digital pathology for oncology decision-making.
Source
EurekAlert
Related News
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.
•EurekAlert
AI-Enhanced Imaging Breaks Barriers in Complex Media for Biomedical Use
Researchers developed a physics-based machine learning imaging system that enhances visibility through complex media, holding promise for biomedical imaging.
•EurekAlert
AI Model Accelerates Accurate Dose Prediction for CyberKnife Radiotherapy
A physics- and spatially informed diffusion model accelerates Monte Carlo–level dose estimation for CyberKnife radiotherapy using planning CT and anatomical data.